

Faculty Disclosures

As an accredited provider of Continuing Medical Education (CME), the Institute for Medical Studies (IMS) requires CME faculty and others in a position to influence the content of the CME activity to disclose any real or apparent conflict of interest related to presentation and discussion content. For this CME activity, resolution of any such conflict of interest has been accomplished through review of the program content by the IMS. For this activity, the following relationships have been disclosed:

Steven D. Gore, MD

Research Sponsorship/Funding: Celgene Corporation and Johnson & Johnson Services, Inc.

Shareholder: Celgene Corporation.

Consultant: Celgene Corporation.

The following author has indicated that she has no relationship that, in the context of her article, could be perceived as a potential conflict of interest:

Evelyn R. Hermes-DeSantis, PharmD, BCPS

Additional disclosures:

John Horton, MB, ChB, served as an independent reviewer and reports no commercial relationship germane to this CME activity.

John M. York, PharmD, Akita Biomedical Consulting, served as the activity planner and reports no commercial relationship germane to this CME activity.

Funding for this monograph has been provided through an unrestricted educational grant from Celgene Corporation. Sponsorship of this monograph does not imply the sponsor's agreement with the views expressed herein. Every effort has been made to ensure that drug usage and other information are presented accurately; however, the ultimate responsibility rests with the prescribing physician. IMS, Akita Biomedical Consulting, Cancer Control Journal, Evelyn R. Hermes-DeSantis, PharmD, BCPS, and Steven D. Gore, MD, shall not be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound at present under clinical investigation.